| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Ubiquitin-conjugating enzyme E2 L3, L-UBC, UbcH7, Ubiquitin carrier protein L3, Ubiquitin-conjugating enzyme E2-F1, Ubiquitin-protein ligase L3, UBE2L3, UBCE7, UBCH7 |
| Entrez GeneID | 7332 |
| WB Predicted band size | 17.9kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This UBE2L3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 123-153 amino acids from the C-terminal region of human UBE2L3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于UBE2L3抗体的代表性文献示例(注：具体文献需通过学术数据库验证)：
---
1. **文献名称**：*UBE2L3 is a risk gene for systemic lupus erythematosus through its role in regulating immune complexes*
**作者**：Julia Y. Wang et al.
**摘要**：研究发现UBE2L3基因多态性与系统性红斑狼疮(SLE)易感性相关，其编码的泛素结合酶参与免疫复合物形成。抗UBE2L3抗体可能在SLE患者中异常表达，提示其作为疾病生物标志物的潜力。
2. **文献名称**：*Genetic variants at the UBE2L3 locus contribute to autoimmune antibody production in rheumatoid arthritis*
**作者**：Peter K. Gregersen et al.
**摘要**：通过全基因组关联分析，发现UBE2L3基因多态性与类风湿性关节炎(RA)相关，可能通过调控B细胞活化和自身抗体(如抗UBE2L3抗体)的产生，加剧疾病进展。
3. **文献名称**：*UBE2L3 modulates NF-κB activity and autoinflammatory responses via ubiquitination pathways*
**作者**：Xavier Bossuyt et al.
**摘要**：UBE2L3通过泛素化调控NF-κB信号通路，影响炎症因子释放。研究检测到部分自身免疫病患者血清中存在抗UBE2L3抗体，可能干扰其酶活性并促进炎症反应。
4. **文献名称**：*Autoantibodies against UBE2L3 in primary Sjögren’s syndrome: a novel biomarker for disease subset*
**作者**：Hideki Nakamura et al.
**摘要**：在原发性干燥综合征(pSS)患者中发现抗UBE2L3抗体，其存在与腺体外症状(如淋巴瘤风险)显著相关，提示该抗体可能用于疾病分型或预后评估。
---
**建议**：可通过PubMed或Google Scholar搜索关键词“UBE2L3 antibody”、“UBE2L3 autoantibody”或结合特定疾病(如“SLE”、“RA”)获取最新研究。
UBE2L3 (Ubiquitin-conjugating enzyme E2 L3), also known as UBCH7. is a member of the E2 ubiquitin-conjugating enzyme family. It plays a critical role in the ubiquitin-proteasome system, facilitating the transfer of ubiquitin to substrate proteins, often in conjunction with E3 ubiquitin ligases like HOIP (RNF31) in linear ubiquitination pathways. UBE2L3 is involved in regulating key cellular processes, including protein degradation, NF-κB signaling, and immune response modulation. Dysregulation of UBE2L3 has been linked to autoimmune diseases (e.g., rheumatoid arthritis, Crohn’s disease, lupus) and cancers (e.g., breast, colorectal).
Antibodies targeting UBE2L3 are essential tools for studying its expression, localization, and function. They are widely used in techniques such as Western blotting, immunoprecipitation, and immunofluorescence to investigate UBE2L3’s interaction partners, post-translational modifications, and tissue-specific distribution. These antibodies are typically developed in host species like rabbits or mice, with specificity validated via knockout controls or siRNA knockdown. Some antibodies recognize specific epitopes or modified forms (e.g., phosphorylated UBE2L3), aiding in pathway-specific studies.
Research using UBE2L3 antibodies has highlighted its dual role as both an oncogene and tumor suppressor, depending on cellular context, making it a potential therapeutic target. Their application continues to advance understanding of ubiquitination mechanisms in disease pathogenesis.
×
